Restless leg syndrome and itching in maintenance hemodialysis patients
Conditions
Interventions
Gabapentin group:100mg~300mg/time, maximum not exceeding 500mg, orally administered after dialysis, 3 times a week.
Pregabalin Group:75mg~150mg/time, orally taken after dialysis, 3 times a week.
Nefarafenib group:2.5ug-5.0ug/time, take orally after dinner or before bedtime, once a day.
Sponsors
The Second Hospital of Tianjin Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1.Age range: 18-75 years old, gender not limited; 2.Maintenance hemodialysis for >= 3 months, 3 times a week; 3.Patients with moderate to severe RLS and/or UP who meet the diagnostic criteria of the International RLS Research Group; 4.Voluntarily sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1.Allergies to research drugs; 2.Severe liver dysfunction, infection, and malignant tumors; 3.Pregnant or lactating women; 4.Unable to cooperate due to mental illness or cognitive impairment; 5.Recently participated in other clinical trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in IRLS score from baseline after 8 weeks of treatment; | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in VAS score;Incidence of adverse events;Laboratory index changes; | — |
Countries
China
Contacts
Public ContactHaibo Yu
The Second Hospital of Tianjin Medical University
Outcome results
None listed